Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Other Accumulated Expenses: 2022-2025

Historic Other Accumulated Expenses for bioAffinity Technologies (BIAF) over the last 3 years, with Sep 2025 value amounting to $28,658.

  • bioAffinity Technologies' Other Accumulated Expenses fell 33.83% to $28,658 in Q3 2025 from the same period last year, while for Sep 2025 it was $28,658, marking a year-over-year decrease of 33.83%. This contributed to the annual value of $60,035 for FY2024, which is 207.90% up from last year.
  • bioAffinity Technologies' Other Accumulated Expenses amounted to $28,658 in Q3 2025, which was down 74.55% from $112,590 recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Other Accumulated Expenses high stood at $112,590 for Q2 2025, and its period low was $1,751 during Q2 2024.
  • Its 3-year average for Other Accumulated Expenses is $33,814, with a median of $24,078 in 2023.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first slumped by 64.98% in 2024, then spiked by 6,330.04% in 2025.
  • bioAffinity Technologies' Other Accumulated Expenses (Quarterly) stood at $5,852 in 2022, then soared by 233.19% to $19,498 in 2023, then soared by 207.90% to $60,035 in 2024, then slumped by 33.83% to $28,658 in 2025.
  • Its Other Accumulated Expenses was $28,658 in Q3 2025, compared to $112,590 in Q2 2025 and $44,205 in Q1 2025.